Inhibition of STAT3 activation by RKIP in colon cancer

Forum on Immunopathological Diseases and Therapeutics

Volumn 2, Issue 1, 2011, Pages 35-45

  Chatterjee, Devasis ^a   Moen, Erika L ^a   Chin, Y Eugene ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Colon cancer; RKIP; STAT3

Indexed keywords

CAMPTOTHECIN; INTERLEUKIN 6; JANUS KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; METASTASIS; METASTASIS INHIBITION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 79957925067     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.v2.i1.50     Document Type: Article

References (47)

1. Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Gene signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil and irinotecan. J Clin Oncol. 2007;7:773-70.
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7. (Pubitemid 30162806)
4. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995;55:1811-6.
5. Kaufmann SH and Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003;22:7414-30 (Pubitemid 37487167)
6. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol. 2001;13:453-62. (Pubitemid 33027897)
7. Houghton JA. Apoptosis and drug response. Curr Opin Oncol 1999;11:475-81. (Pubitemid 29515892)
8. Green DR, van GI E. A matter of life and death. Cancer. 2002;1:19-30. (Pubitemid 41039172)
9. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillard JA. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-8. (Pubitemid 20042739)
10. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-6.
11. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14:709-15. (Pubitemid 26085513)
12. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol.l 1999;26:647-62,. (Pubitemid 30013272)
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7. (Pubitemid 30162806)
14. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91. (Pubitemid 34438898)
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
16. Hsiang YH, Hertzberg R, Hecht S., Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985l260:14873-8.
17. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem. 2002;277:26553-64. (Pubitemid 34967153)
18. Pantazis P, Chatterjee D, Wyche J, DeJesus A, Early J, Plaschke S, Giovanella B. Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins. J Exp Ther Oncol. 1996;1:322-33. (Pubitemid 126739051)
19. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, Giovanella BC. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res. 1993;53:1577-82. (Pubitemid 23113233)
20. Pantazis P, Early JA, Mendoza JT, DeJesus AR, Giovanella BC. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res. 1994;54:771-6. (Pubitemid 24068335)
21. Zuco V, Supino R, DeCesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F. Cellular basis of the antitumor activity of a 7-substituted camptothecin in hormone-refractory prostate carcinoma models. Biochemical Pharmacology. 2003;65:281-94.
22. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003;22:7414-30. (Pubitemid 37487167)
23. Pantazis P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin Cancer Res. 1995;1: 1235-44.
24. Pantazis P. The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Leuk Res. 1995;19:775-88. (Pubitemid 26009886)
25. Chatterjee D, Wyche JH, Romero DP, Pantazis P. Telomerase activity, Myc and Bcl-2: possible indicators of effective therapy of prostate cancer with 9-nitrocamptothecin. Anticancer Res. 2000;20:2885-9.
26. Chatterjee D, Wyche JH, Pantazis P. Upregulation of cyclin B1 and cdc2 expression during 9- nitrocamptothecin-induced regression of DU145 prostate tumor. Anticancer Res. 2000;20:4477-82. (Pubitemid 32141806)
27. Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, Peter ME, Wyche JH, Pantazis P. Induction of apoptosis in 9-nitrocamptothecin- treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res. 2001;61:7148-54. (Pubitemid 32946508)
28. Rasheed, Z.A. and Rubin, E.H. Mechanisms of resistance to topoisomerasaeI-targeting drugs. Oncogene. 2003;2:7296-304.
29. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996;274:787-9.
30. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem. 2004;279:17515-23. (Pubitemid 38560515)
31. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173-7. (Pubitemid 29436321)
32. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and Tak1 and inhibits NFkappaB activation. Mol Cell Biol. 2001;21: 7207-17. (Pubitemid 32953475)
33. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of Raf kinase inhibitor protein expresion on suppression of prostate cancer metastasis. J Nat Cancer Inst. 2003;95:878-83.
34. Keller ET, Fu Z, Yeung K, Brennan M. Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett. 2004;207:131-7. (Pubitemid 38457033)
35. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ, Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res. 2005;11:7392-7. (Pubitemid 41507699)
36. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A. Loss of Raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol. 2007;127:820-7.
37. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, García JJ, Scott L, Fyfe N, Murray GI, Kolch W. Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J. Clin. Oncol. 2006;24:5672-9.
38. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 2004;64:5186-92. (Pubitemid 39006537)
39. L expression. Cancer Res. 2004;64:7117-26.
40. Rivat C, Rodrigues S, Bruyneel E, Piétu G, Robert A, Redeuilh G, Bracke M, Gespach C, Attoub S. Implication of STAT3 signaling in human colonic cancer cells during Intestinal Trefoil Factor 3 (TFF3) and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 2005;65:195-202
41. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;3:2000-8. (Pubitemid 34270888)
42. Buettner R, Mora LB, Jove R. Activated signal transducers and activaors of transcription signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945-54. (Pubitemid 35177340)
43. Yuan Z, Guan Y, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-273. (Pubitemid 40116244)
44. Duhe RJ, Wang LH, Farrar WL. Negative regulaton of Janus kinases. Cell Biochem. Biophys. 2001;34:17-59.
45. Silver DL, Montell DJ. Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in Drosophila. Cell. 2001;107:831-41. (Pubitemid 34084975)
46. Constancio-Lund SS, Brabek J, Hanks SK. Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background. Mol Carcinog. 2009;48:56-66.
47. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998,5:545-52.